Predictive Technology Group, Inc. (PRED) Announces US Patent for Method for Performing an Advanced Reproductive Therapy Supporting Licensed Technology from Juneau Biosciences

Acquisition Strengthens Commercialization Strategy of Company’s Gene Therapy Products

Salt Lake City, UT — (January 12, 2017) – Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, announces the issuance of US patent 9,434,991 direct to a method for performing an Advanced Reproductive Therapy (“ART”).

The Centers for Disease Control and Prevention (”CDC”) estimates 208,604 ART cycles were performed in 2014 resulting in 70,354 live births in the United States in 2014. Mike Schramm, PRED’s Director of Intellectual Property, described the claims of 9,434,991 as covering any in vitro fertility treatment of an egg of a woman having any gynecological disorder associated biomarker.

“The issuance of this US patent significantly strengthens PRED’s Intellectual Property position and mission of assisting parents in delivering the healthiest babies possible,” said Bradley Robinson, President and Chief Executive Officer of PRED. “The rights to this technology are seen as a synergistic companion to our medicinal therapeutic products.”

According to Technavio’s latest report, the global fertility services market is expected to exceed USD 21 billion by 2020, growing at a CAGR of almost 9% during the forecast period.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL at 757-306-6090, yes@yesinternational.com, www.predictivetechnologygroup.com, www.predrx.com, and www.yesinternational.com.

 Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

 

Northstar Electronics Recap of Main Events of 2016

Virginia Beach, VA, Jan. 10, 2017 (GLOBE NEWSWIRE) — Northstar Electronics, Inc.(NEIK:OTCQB), the “Company”,  provides a Recap of the main events of 2016.

To summarize, the Company’s primary objectives for 2016 were two fold. One was to improve the Company’s standing as a publicly traded platform. The second was to make significant progress for the Company’s subsidiary, Northstar Sealand Enterprises Ltd. (NSEL), to secure the exclusive worldwide ownership rights to the enhanced version of a single engine Turbo-Prop industrial airplane owned by the subsidiary of a major international aerospace company. NSEL intends to manufacture, market and sell the airplane and also carry out Maintenance, Repair and Overhaul (MRO) services.

During the year, the Company achieved its goals of becoming current with its SEC filings and returning to the OTCQB trading platform, actions fundamental to the Company’s future success.

With respect to the acquisition of the rights to the airplane, significant progress was made on key matters. Agreement with the aerospace company subsidiary was reached during the year on the main technical issues. As well, strong progress was made on project scheduling and cost estimates.

At year’s end, NSEL and the aerospace company subsidiary signed a milestone Memorandum of Understanding (MOU). The MOU outlines the key actions and goals to be reached in order for both parties to implement their business plans going forward. The signing of this MOU is a major step which ultimately should lead to NSEL reaching its manufacturing and marketing objectives within a reasonable time frame.

GOALS FOR 2017

The Company’s goals for NSEL in 2017 are to finalize the acquisition of the exclusive worldwide rights to the Turbo Prop industrial airplane and initiate the transfer of the Type Certificate to NSEL, to initiate the establishment of first order technical support, to put in place a Supply Chain Management system, to initiate the marketing campaign and to secure the first sales orders for the airplane.

We will be approaching institutional investors and venture capital companies for the funding needed to grow the company. As well, we will explore funding opportunities through certain government support programs.

About Northstar Electronics, Inc.

Northstar was established in the late 1990’s. The Company has carried out design and manufacturing contracts for various divisions of Lockheed Martin Corporation including LM MS2 (Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Parts for P-3 Orion Airplane), and L-3 ( Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its own sonar-based system to commercial customers. Since termination of the above contracts Northstar has been seeking other strategic relationships

Safe Harbor Statement:

This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.

For further information about this news release contact:

Rich Kaiser, Investor Relations, Yes International, 757-306-6090, yes@yesinternational.com

Predictive Technology Group, Inc. (PRED) Announces Acquisition of US Patent Application for Method for Treating Patients with Stem Cells “Cleaned” via CRISPR

Acquisition Strengthens Commercialization Strategy of Company’s Gene Therapy Products

Salt Lake City, UT — January 10, 2017 – Predictive Technology Group, Inc. (OTCPINK: PRED), a life sciences technology holding company, announced the acquisition of US patent application 62/295,042 direct to the practice of “cleaning” stem cells of a predetermined disease-associated marker via theClustered Regularly Interspaced Short Palindromic Repeats CRISPR” process and administering the stem cells to the patient.

“Clustered Regularly Interspaced Short Palindromic Repeats” (CRISPR) technology offers several advantages over previous forms of gene-editing. The human cell’s genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. Unlike other current practices which involve the introduction of foreign DNA.

“The claims are drawn to the ’cleaning‘ of any stem cell having a predetermined disease associated biomarker,” said Mike Schramm, PRED’s Director of Intellectual Property.  “Because the patent application is for both autologous (withdrawn from and reintroduced to the same patient) and homologous (derived from another source), we see very broad use of the application.”

These rights enable PRED to both diagnose a patient for a genetic disease based on a specific biomarker and subsequently treating the patient with their own stem cells having the diagnosed biomarker eliminated via the CRISPR method.

“This is a significant opportunity for our company to obtain the rights to this invention,” said Bradley Robinson, President and Chief Executive Officer of PRED. “The technology is a strong bridge between our Molecular Diagnostic and Regenerative Medicine product portfolios.”

The global genome editing market is expected to reach USD $5.54 Billion by 2021 from USD $2.84 Billion in 2016, growing at a CAGR of 14.3%. (Source: Market and Market 2016 Genome Editing and Genome Engineering Report)

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com and www.predictivetechnologygroup.com. 

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

 

BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH) ANNOUNCES NEW PRESIDENT/CEO /CHAIRMAN

Virginia Beach, VA- January 3, 2017- BioForce Nanosciences Holdings, Inc. (BFNH.OTCPINK) announces Mr. Merle Ferguson as its new President/ CEO / Chairman.  Mr. Ferguson brings to BFNH business acumen from both the public and private business arenas.

Further, BioForce Nanosciences Holdings, Inc.’s business focuses on the acquisition of services, productions, and agricultural facilities within the food services sector.

For further information about this release, contact YES INTERNATIONAL, Investor Relations, 757-306-6090, yes@yesinternational.com and www.yesinternational.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain forward information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competitions.

NORTHSTAR ELECTRONICS, INC. SIGNS MEMORANDUM OF UNDERSTANDING WITH MAJOR AEROSPACE COMPANY

 Virginia Beach, VA– December 20, 2016- Northstar Electronics, Inc.,(OTCQB:NEIK), the “Company” is pleased to announce that it has signed a Memorandum of Understanding (MOU) with a subsidiary of a major international Aerospace Company.

Northstar Electronics’ subsidiary, Northstar Sealand Enterprises Ltd (NSEL), has the objective of acquiring the exclusive world-wide rights to an enhanced version of a single engine Turbo-Prop industrial airplane from the subsidiary of the international aerospace company.

NSEL would manufacture, market and sell the airplanes and also carry out Maintenance, Repair and Overhaul (MRO). The MOU outlines key actions and goals to be reached in order to implement this new business plan for the Company.

The signing of this MOU is a first step which ultimately should lead to NSEL reaching its manufacturing and marketing goals within a reasonable time period.  As part of the overall new focus of the Company, NSEL would also implement a strong marketing and sales campaign to maximize early orders for the new version of the airplane.

As more information becomes available and further developments occur between Northstar Electronics and the Aerospace Company, shareholders and other interested parties will be promptly notified on the progress in accordance with guidelines and requirements indicative for publicly traded companies.

For further information about this news release contact:

Rich Kaiser, Investor Relations, Yes International, 757-306-6090, yes@yesinternational.com

 

About Northstar Electronics, Inc.

Northstar was established in the late 1990’s. The Company has carried out design and manufacturing contracts for various divisions of Lockheed Martin Corporation including LM MS2 (Submarine Command and Control Consoles), LM Canada (Naval Anti-Terrorism System), LM Aeronautics (Parts for P-3 Orion Airplane), and L-3 ( Navy Frigate Command and Control Consoles). Northstar also designed, manufactured, and sold its own sonar-based system to commercial customers. Since termination of the above contracts Northstar has been seeking other strategic relationships

Safe Harbor Statement:

This press release may include predictions, estimates, opinions or statements that might be considered “forward-looking” under the provisions of the Private Securities Litigation Reform Act of 1995. Such statements generally can be identified by phrases such as the Company or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates,” or other, similar words or phrases.

Predictive Technology Group, Inc. (PRED) Retains Stevenson & Company CPAs

Stevenson & Company CPAs will act as independent auditors of Predictive Technology Group, Inc.

Salt Lake City, UT — (December 20, 2016) – Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, announces the Company has retained Stevenson & Company CPAs as its PCAOB auditing firm.

Stevenson & Company CPAs will act as independent auditors as required to become a fully reporting company under US SEC rules.

Upon completion of the audited financial statements and other legal narratives required to become fully reporting, The Company will transmit its registration statement to the US SEC for approval.

For further information, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090, yes@yesinternational.com and www.predictivetechnologygroup.com.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future. The Company does not undertake any obligation to provide an update with respect to any potential legal or financial transactions, except as required under the applicable law.

 

 

Bravo Multinational Incorporated (BRVO) – Update  

Toronto, Canada – December 19th, 2016- Bravo Multinational Incorporated (OTCQB: BRVO) reports on Company activities.

10Q for Quarter ending September 30, 2016:

The Company would like first to apologize to its shareholders for the yet to be filed “Quarterly Report.” The cause of this extensive delay is due to serious ongoing health issues with BRVO’s CFO. That being said, after numerous interviews with several firms over the past few weeks, the Company has on Friday, December 16, 2016, finalized the engagement of a new accounting firm that will immediately take over the full accounting duties of the Company. This new firm located in New York State has extensive US SEC accounting experience.  Management welcomes the new addition to the Bravo team. The Company’s PCAOB auditing firm, Scrudato & Co., PA-Certified Public Accounting Firm, has not changed.

El Salvador- Central America:

The gaming license operational openings in municipalities in the capital city of San Salvador, El Salvador will be delayed due to current circumstances out of the Company’s control. The parties that were to fund and open the two locations have decided to hold off on the location openings. Bravo’s management has worked with the El Salvadoran associates for the past year to plan this new business venture and hope to have the licenses put to work, shortly.

Equipment Sales:

BRVO sales division for gaming equipment reports that Q4 is moving well within anticipated projections.  Management looks forward to furthering future sales growth going into, and throughout 2017.

OTCQB Status:

The Company has had many inquiries regarding the Company’s OTCQB status due to the late filing and the sub-penny share price. The OTCQB status will be maintained and immediately regained as soon as the filings are up- to- date.  As for the share price, the Company has six months to regain a level of one cent (0.01) to maintain the OTCQB status.

 

Market Stock Selling/buying:

Recently, the Company is aware of certain large shareholders (non-affiliates) that have informed the Company that they have chosen to divest in Bravo at this time to take advantage of year-end tax planning, as well as, to move on to alternate investments. This trading activity resulted in more than 15 million shares being put onto the open market, recently.  Before this occurring, the last couple of weeks the Company feels that significant short selling pressure started in mid-September, adding to the share price declines. The Company has no control over free-trading share sales.

Core Business Focus:

BRVO continues its positive efforts to increase revenues and intends to grow the core gaming equipment business throughout next year and bring forth a strong balance sheet for 2017.  Q4 2016 should report positive sales growth. Additionally, the company has made arrangements to enhance its equipment sales operation, by opening an independent Bravo sales office in the New Year.   Regardless of the current share price, the core business is growing, and BRVO anticipates extensive growth throughout 2017.

About Bravo Multinational Incorporated:

Bravo Multinational Incorporated (OTCQB: BRVO) is a diversified Company, with its main focus on the development and expansion of the Casino Gaming Equipment holdings and Gaming related business activities throughout Central and South America. Bravo’s growth strategy, driven by partnerships, acquisitions, and new ventures should result in financially viable and profitable corporate divisions.

Bravo Multinational Incorporated cautions that the statements made in this press release and other forward looking statements made on behalf of the Company may be affected by such other factors including, but not limited to, vagaries of trade, market competition and other risks detailed herein and from time to time in the U.S. Securities and Exchange Commission filings of the Company.

 

Predictive Technology Group, Inc. (PRED) Announces Notice of US Patent Allowance for Method for Treating Patients with Genetic Spinal Deformities and Syndromes

Allowance Strengthens Commercialization Strategy of Company’s Proprietary Diagnostics and Therapeutics

Salt Lake City, UT — (December 16, 2016) – Predictive Technology Group, Inc. (OTC PINK: PRED), a life sciences technology holding company, announced today that the United States Patent and Trademark Office (USPTO) has allowed a fundamental patent application – US20160296671 -that covers the practice of administering “ANY” spine deformation therapeutics to a patient having a spine deformation altered risk associated biomarker.

“We are pleased to see this latest allowance that supports PRED’s novel approach to diagnosing spinal disorders and syndromes, “said Mike Schramm, PRED’s Director of Intellectual Property. “This allowed US patent application supports the commercial use of both our diagnostic and next-generation companion treatment products.”

The claims of the ‘671 application build on previously issued US patents 8,123,787, 8,641,738, and 9,370,431 to which ‘671 claims priority and further bolster Predictive Technology Group’s Intellectually Property position.

“We are gratified to see this latest application allowance, which covers the core technology underlying the Company’s molecular diagnostic test” said Bradley Robinson, President and Chief Executive Officer of Predictive Technology Group, Inc. “Furthermore, this fundamental patent covers not only spinal applications of our technology but establishes a precedent for the other patent applications that have been submitted on the Company’s portfolio of next-generation diagnostic and companion treatment products.”

The allowance of this new application is a significant milestone for Predictive Technology Group.  The patent establishes the foundation of key intellectual property (IP) covering ANY treatment options (drug, surgery, bracing, etc.) for patients having a specific spine deformity biomarker.  This newly allowed application is additive to previously announced patents.  Furthermore, the Company has additional US and International patent applications pending and will pursue such applications with the objective of receiving additional issued patents in additional disease states.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases, www.predictivetechnologygroup.com

For more information about PRED, contact Mr. Richard Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Weyland Tech (WEYL) Enters Into Strategic Partnership with Express & E-Commerce Solutions Provider

Hong Kong —December 6, 2016 — Weyland Tech Inc. (OTCQB: WEYL) (“Weyland Tech” or the “Company”), a provider of mobile business applications, announces that it has entered into a Strategic Partnership with DPEX Worldwide, a leading provider of express and E-Commerce solutions in Asia.

DPEX Worldwide in collaboration with WEYL will together offer a Mobile Commerce (“m-commerce”) solution coupled to a logistics solution. This will provide users subscribing to the application with a one-stop end-to-end solution incorporating m-commerce setup and operation, payment gateways for m-commerce transactions, logistics services such as warehousing, fulfillment, cross border and domestic distribution.

About Weyland Tech Inc.

Weyland Tech’s “CreateApp” platform is focused on the Asia markets. Our CreateApp platform is offered in 12 languages and enables small-medium-sized businesses (“SMB’s”) to create a mobile application (“APP”) without the need of technical knowledge and background. SMB’s can increase sales, reach more customers and promote their products and services via a simple easy to build mobile APPs in an affordable and cost-effective manner, www.weyland-tech.com.

About DPEX Worldwide

DPEX Worldwide is an established Express and E-Commerce solutions provider in Asia providing a wide array of solutions and services catering to the growing need for seamless end to end logistics requirements by customers today.

With a history and experience dating 30 years and a comprehensive network spanning 17 countries in the region, DPEX Worldwide has extensive local knowledge to serve into and throughout Asia.

DPEX Worldwide is widely acknowledged as “Knowing Asia, Delivering Asia.” From Asia to the world, DPEX Worldwide is positioned and poised to be a leading total solutions provider in the region, able to cater to the requirements for both cross border and domestic logistics solutions.

For further information about Weyland Tech, Inc., contact Rich Kaiser, Investor Relations, YES INTERNATIONAL 757-306-6090 (001-757-306-6090), yes@yesinternational.com,info@weyland-tech.com and http://www.weyland-tech.com.

Safe Harbor Statement
This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.

Weyland Tech (WEYL) Expands Management Team

Hong Kong, China- 2016 — Weyland Tech Inc. (OTCQB: WEYL) (“Weyland Tech” or the “Company”), a provider of mobile business applications is pleased to announce the expansion of the management team with key hires possessing solid backgrounds in software, video gaming, investment analysis and business/corporate development.

Joining the Company as Chief Technology Officer – Mr. Thet Twe Aung.

In addition, we expanded our Corporate and Business Development & Strategy team with the addition of Mssrs. Matthew Brent and Jason Chang, and our Capital Markets and Strategy team added Mr. John MacNeil.

Thet Twe Aung

Spending 10 years in software development industries, Thet has in-depth knowledge in various development methodologies, software design patterns, data modeling and hands-on experience with mobile/web programming, socket programming, frameworks, SDKs and APIs. In 2015, he founded and served as a CEO of Escape Pixel, a digital startup in Singapore that provides customized digital solutions to enterprises and businesses. With the vision to shape the future of its community, he is also an active contributor/developer of many open source software projects which advance linguistic evolution, localization, and cognition.

Thet holds a Bachelor of Science with honors degree in Business Computing and Information Technology from the University of Wales, Prifysgol Cymru.

Mr. Jason Chang

Jason has been in the technology, corporate strategy, product management, sales, and marketing sector for over 18 years. Started his career in Silicon Valley with various startups and his last position was the Regional Head for National Sales in Groupon Asia, a NASDAQ listed company. He oversaw sales, partnerships, business development and handled strategic accounts for Groupon’s top merchants. Jason has led regional teams in Singapore, Malaysia, Indonesia, Taiwan and Hong Kong.  He received his Bachelor’s degree from University of California, Berkeley.

Mr. Matthew Brent

Matt has over 10 years’ experience in software and product development across the US and Asia, working with local and remote teams to deliver global product for entertainment, media and technology companies such as Sony Computer Entertainment America, Activision Blizzard, The Upper Deck Company, and The Sesame Street Workshop. He has held senior creative, production, and operational roles at both bootstrapped startups and well-capitalized multinationals, most recently shipping a therapeutic neurofeedback program designed for children with attention deficit disorder. He received his Bachelor’s of Philosophy from the University of Illinois, Chicago.

Mr. John MacNeil

John MacNeil has established extensive experience in the financial services and technology industries over the course of a thirty-year career. From 2008 to present, John advised technology, financial technology, and renewable energy companies on strategic relationships, financial forecasting, investor relations and capital formation.

Prior, John was a Vice President at Schroders Investment Management (1999-2008) where he was Portfolio Manager for the $300 million global technology fund (2003-2008) and the emerging technology fund. Before joining Schroders, John was an Equity Strategist (1993-1999) at UBS/PaineWebber and Citigroup/Salomon Smith Barney focusing on areas of asset allocation and technology investment. He holds an MBA from Columbia Business School, as well as a BSEE from University of Connecticut.

About Weyland Tech Inc.

Weyland Tech’s “CreateApp” platform is focused on the Asia markets. Our CreateApp platform is offered in 12 languages and enables small-medium-sized businesses (“SMB’s”) to create a mobile application (“APP”) without the need of technical knowledge and background. SMB’s can increase sales, reach more customers and promote their products and services via a simple easy to build mobile APPs in an affordable and cost-effective manner, www.weyland-tech.com/.

For further information about Weyland Tech, Inc., contact Rich Kaiser, Investor Relations, YES INTERNATIONAL 757-306-6090 (001-757-306-6090), yes@yesinternational.com,info@weyland-tech.com and http://www.weyland-tech.com/.

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.